From JPMA JPMA Press Conference on the Establishment of an Action Fund for AMR

The event for the establishment of the "Drug Resistance (AMR) Action Fund," a groundbreaking partnership aimed at providing patients with two to four new antibiotics by 2030, was held on July 10, 2020 at the Hotel Metropolitan Edmont (Tokyo, Japan) in the form of a press conference organized by the JPMA. Chiyoda-ku, Tokyo) on July 10, 2020, in the form of a press conference hosted by the Pharmaceutical Manufacturers Association of Japan. In addition to the background and purpose of the AMR Action Fund, leading figures from industry, academia, and government provided information on the lessons we are learning from the global spread of COVID-19 and the need to prepare for new infectious disease outbreaks that may occur in the future. Leading experts from industry, academia, and government provided information on what we are learning and the need to be prepared in parallel to prepare for possible new infectious disease outbreaks in the future.

The AMR Action Fund, established by more than 20 global biopharmaceutical companies, will raise nearly US$1 billion to support research and development of innovative new antibiotics to combat the most resistant bacteria and life-threatening infectious diseases. The fund has been endorsed by the World Health Organization (WHO), the European Investment Bank (EIB), and the Wellcome Trust Foundation.

The series of events, led by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in collaboration with national and regional industry associations, was held simultaneously in Washington, D.C., USA and Berlin, Germany, on July 9, 2020, and was broadcast live worldwide via the Internet. The event was broadcast live worldwide via the Internet. The press conference in Japan was also streamed live, and was viewed by many people, including media representatives who attended the press conference.

(From the JPMA press conference "Lessons Learned from the Spread of the New Coronavirus and Preparations for Drug Resistance (AMR)" held on July 10, 2011)